Rebound In COVID-19 Symptoms After Pfizer's Antiviral Pill Might Be Due To Stronger Immune Response

  • Reports are circulating related to recurring COVID-19 symptoms after completing treatment and experiencing improvement after Pfizer Inc's PFE COVID-19 oral antiviral Paxlovid. 
  • President Joe Biden and National Institute of Allergy and Infectious Diseases Director Dr. Anthony Fauci both experienced a COVID rebound after taking Paxlovid.
  • The U.S. government researchers have found that the rebound may be related to a robust immune response rather than a weak one, Reuters reports.
  • Also read: Pfizer's COVID-19 Pill Benefited Only Older Adults, New Israel-Based Study Shows.
  • The researchers concluded that taking a longer course of the drug - beyond the recommended five days - was not required to reduce the risk of a recurrence, based on an investigation of a rebound in eight patients at the National Institutes of Health's Clinical Center.
  • The FDA asked Pfizer to test an additional course of Paxlovid among people who experience a rebound in COVID-19 after treatment.
  • The repot added that all patients in the study had developed robust immune responses but higher levels of antibodies in the patients who experienced a rebound.
  • None of the rebound patients required additional treatment or hospitalization.
  • Price Action: PFE shares are down 1.57% at $42.42 on the last check Friday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechLarge CapNewsHealth CareGeneralBriefsCOVID-19 Coronavirus
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!